BGI Partners With Life Technologies to Offer Faster, More Affordable Sequencing Applications on Ion Torrent™ -- World's largest genome center to purchase 50 Ion Proton™ Sequencers from Life Technologies--
CARLSBAD, Calif., Oct. 21, 2013 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) and BGI, the world's largest genomics center and service provider, jointly announced that BGI has purchased 37 Ion Proton™ Sequencers and plans to add at least a dozen more by the end of the year, strengthening the organization's leadership position in the genomics industry. BGI also signed a supply and licensing agreement with Life Technologies, further enhancing BGI's ability to perform basic, agricultural and clinical research.
The addition of the Ion Torrent™ to BGI's current broad array of technology platforms will facilitate its goal of accelerating and expanding the organization's strong presence in all areas of next-generation sequencing and clinical research, ranging from exome and transcriptome sequencing to aneuploidy testing to whole genome analysis.
BGI has already validated the Ion Proton™ System in several applications. The Ion Proton™ Sequencer has consistently delivered over 80 million high-quality sequencing reads in 2-3 hour sequencing runs on the Ion PI™ Chip in BGI's labs.
"We have been working with the Ion Proton™ platform on major applications for the last several months and it has passed every test," said Jun Wang, director of BGI. "It is flexible and affordable, so we can quickly deploy it in many satellite labs around the world for all applications. The Ion Proton™ is also very fast, enabling us to provide our customers and partners results in days, not weeks, which is extremely important for clinical research applications. The upcoming Ion PII™ Chip is expected to significantly expand sequencing capacity on the same Ion Proton™ Sequencer and our plan is to migrate additional applications to the Ion Proton platform."
"BGI's commitment to the Ion Proton™ platform is the ultimate validation that our breakthrough benchtop sequencing technology delivers more value than the big sequencers that have dominated the market for so long," said Life Technologies' Chairman and Chief Executive Officer Gregory T. Lucier. "By setting a new standard for speed, simplicity, price and performance, the Ion Proton™ System has become the choice of the world's largest genomics center, and yet it's still accessible to virtually any lab."
In just three years, Ion Torrent™ has become the bestselling benchtop sequencer brand in the world by bringing the transformative power of semiconductor technology to sequencing. The Ion Proton™ Sequencer is just a fraction of the cost of other sequencers to buy and to run, and it delivers sequence in just a few hours, compared to 10 days or more for competitors. This makes Ion Torrent™ technology ideal for both small labs and large-scale platform developer like BGI.
The Ion Proton™ System is For Research Use Only, not intended for diagnostic purposes.
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents and licenses that span the entire biological spectrum—scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012.
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Life Technologies Corporation
BGI was founded in 1999 with the simple vision of using genetic technology to benefit the human race. The mission of BGI is predicated upon its high-throughput, low-cost genomics platform, combined with a formidable data production capacity allowing its cutting edge research to synergize with state-of-the-art genetic testing. Combined with an unprecedentedly large sample collection and storage capability, an integrated approach to bioinformatics analysis, a commitment to education, media liaison, and a fundraising effort to support its highly ambitious scientific program, BGI has created a unique entity that is dedicated to ensuring that omics science and technology can be made to work for the benefit of everyone. For more information, visit www.genomics.cn
SOURCE Life Technologies Corporation